XM does not provide services to residents of the United States of America.

Most Asian FX set for monthly gains; US PCE data in focus



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>RPT-EMERGING MARKETS-Most Asian FX set for monthly gains; US PCE data in focus</title></head><body>

.

Malaysian ringgit eyes best month since March 2016

Most Asian shares trade higher

Indonesian rupiah on track for best month since April 2020

By Adwitiya Srivastava and Archishma Iyer

Aug 30 (Reuters) -Most emerging Asian currencies were set on Friday for monthly gains despite falling during the day, while the U.S. dollar was poised for its worst month in nine as markets priced in a definite rate cut by the Federal Reserve in September.

The dollar index =USD has depreciated nearly 2.7% in August as investors anticipate a decline in U.S. interest rates.

August was a bumpy road for financial markets, after worrisome U.S. data at the start of the month triggered concerns of a recession.

Moreover, the Bank of Japan's unanticipated rate hike led to a massive unwinding of carry trade in the Japanese yen, which weighed heavily on the dollar.

In emerging Asian markets, the Malaysian ringgit MYR= has had a stellar run with a year-to-date gain of nearly 6.5% and its strongest monthly performance since March 2016, while the Indonesian rupiah IDR= was set for its best month since April 2020.

"What gives us some comfort that this is a broad dollar decline is the fact that the Asian FX laggards are all participating in the move," ING analysts wrote in a note.

On Friday, however, most emerging Asian currencies fell against a stronger dollar after robust economic data from the U.S. overnight led the market to pull back bets on aggressive rates by the Fed. FRX/

The Indonesian rupiah IDR= dipped about 0.3%, while the South Korean won KRW=KFTC and Taiwan dollar TWD=TP both fell about 0.2%.

"I still do think the biggest driver in Asian currencies going forward will be the changes in the U.S.," said Gary Ng, a senior economist at Natixis.

"I think the market has been pricing the aggressive Fed rate cut a bit too far in Asia, so it's possible to see some pullback in Asian currencies," he added.

Traders are now wagering more on a 25 basis point rate cut in the upcoming Fed meeting than a 50 bps cut.

Market participants are awaiting U.S. personal consumption expenditures (PCE) index data showing the Fed's preferred measure of inflation due later on Friday and a key labour market report next week for fresh cues on the Fed's interest rate trajectory.

In Asia, Malaysia's central bank is set to conduct its monetary policy meeting next week.

Asian equities traded higher on Friday in line with global shares. Chinese stocks .SSEC led the gains, rising about 1.3%, while key indexes in Malaysia .KLSE, South Korea .KS11 and Singapore .STI traded between 0.3% and 0.7% higher.

Regional markets will witness a string of inflation data from different countries next week, including Indonesia, Taiwan, Thailand and South Korea, which could provide clarity on their respective interest rate paths.


HIGHLIGHTS:

** Core inflation in Japan's capital perks up, backs case for BOJ hikes

** Thai central bank chief, finance minister to meet over inflation target as govt eyes rate cut

** India's June qtr GDP growth likely slowed on reduced government spending


Asian stocks and currencies at 0513 GMT

COUNTRY

FX RIC

FX DAILY %

FX YTD %

INDEX

STOCKS DAILY %

STOCKS YTD %

Japan

JPY=

+0.12

-2.58

.N225

0.36

15.05

China

CNY=CFXS

+0.10

+0.10

.SSEC

1.34

-3.83

India

INR=IN

+0.01

-0.78

.NSEI

0.24

16.02

Indonesia

IDR=

-0.26

-0.36

.JKSE

0.41

5.31

Malaysia

MYR=

-0.05

+6.50

.KLSE

0.31

14.02

Philippines

PHP=

+0.12

-1.32

.PSI

0.38

7.25

S.Korea

KRW=KFTC

-0.19

-3.52

.KS11

0.69

0.96

Singapore

SGD=

+0.03

+1.30

.STI

0.55

5.65

Taiwan

TWD=TP

-0.21

-3.87

.TWII

0.54

24.48

Thailand

THB=TH

-0.31

+0.46

.SETI

0.35

-3.79





Reporting by Adwitiya Srivastava in Bengaluru; Editing by Jamie Freed

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.